Detalles de la búsqueda
1.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35658005
2.
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Cancer
; 120(14): 2164-73, 2014 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24752867
3.
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Cancer Discov
; : OF1-OF12, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587856
4.
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
Clin Cancer Res
; 29(16): 3074-3080, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37279096
5.
Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
Cancer Discov
; 13(1): 41-55, 2023 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36355783
6.
Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.
J Proteome Res
; 11(7): 3637-49, 2012 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-22663298
7.
Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.
Blood
; 116(15): 2724-31, 2010 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-20660292
8.
Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Biochemistry
; 50(39): 8478-88, 2011 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21870818
9.
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.
Biochem Biophys Res Commun
; 415(1): 163-7, 2011 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-22027148
10.
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Mol Cell Biochem
; 356(1-2): 37-43, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21755459
11.
Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties.
Bioorg Med Chem Lett
; 21(6): 1687-91, 2011 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21316963
12.
7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Bioorg Med Chem Lett
; 21(22): 6687-92, 2011 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21982499
13.
Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.
Clin Cancer Res
; 15(1): 238-46, 2009 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19118051
14.
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
Mol Cancer Ther
; 7(8): 2394-404, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18723486
15.
Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors.
J Med Chem
; 50(22): 5253-6, 2007 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17887663
16.
Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
J Med Chem
; 49(11): 3362-7, 2006 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16722655
17.
Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha.
Biomark Insights
; 11: 7-18, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26848256
18.
Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.
J Med Chem
; 45(26): 5755-75, 2002 Dec 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-12477359
19.
Beyond VEGF: targeting tumor growth and angiogenesis via alternative mechanisms.
Adv Exp Med Biol
; 610: 43-53, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18593014
20.
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Cancer Lett
; 322(1): 113-8, 2012 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22387988